1
ORAL PRESENTATION Open Access AMPK - a nutrient and energy sensor with roles in diabetes, cancer and viral infection Grahame Hardie From Metabolism, diet and disease Washington, DC, USA. 29-31 May 2012 The AMP-activated protein kinase (AMPK) is a cellular energy sensor that is conserved throughout the eukaryotic domain. AMPK exists as complexes comprising catalytic a subunits and regulatory b and g subunits, which are acti- vated >100-fold by phosphorylation of the a subunit at Thr-172 by upstream kinases. Binding of AMP to one site on the Y subunit causes 10-fold allosteric activation by AMP, while binding of either AMP or ADP to a second site promotes phosphorylation and inhibits dephosphory- lation of Thr-172. Since both effects are antagonized by ATP, the kinase is activated by falling cellular energy sta- tus, when it phosphorylates downstream targets that switch on catabolic pathways generating ATP, while switching off processes consuming ATP. Catabolic pro- cesses switched on including uptake and metabolism of glucose and fatty acids, and mitochondrial biogenesis. ATP-consuming processes switched off include biosyn- thetic pathways for lipids (fatty acids, phospholipids, cho- lesterol), carbohydrates (gluconeogenesis, glycogen synthesis), proteins and ribosomal RNA, and progress through the cell cycle. By switching on glucose and fatty acid uptake and meta- bolism and switching off gluconeogenesis, AMPK should reverse the key metabolic defects in insulin resistance and type 2 diabetes. Consistent with this, AMPK is a target, although probably not the only target, for the anti-diabetic drug metformin. Because AMPK activation inhibits most biosynthetic pathways and causes cell cycle arrest, it should also have a cytostatic, tumor suppressor effect. The discovery in 2003 that the major upstream kinase that phosphorylates Thr-172 is the tumor suppressor kinase, LKB1, strengthened this view. The finding also led to ret- rospective analyses suggesting that metformin protects against the development of cancer. If AMPK is a tumor suppressor, one would expect that it would be down-regulated in many tumors. This indeed occurs through loss-of-function mutations in the upstream kinase LKB1, particularly in non-small cell lung cancer and cervical cancer. The majority of cases of breast cancer also appear to have defects in AMPK activation, although the mechanism is not known. We have found that AMPK is down-regulated in cells infected with hepatitis C virus (HCV). HCV may switch off AMPK to prevent its inhibi- tory effects on lipid and protein synthesis, required for viral replication. HCV infection activates the PKB/Akt pathway, leading to phosphorylation of the a1 subunit of AMPK on Ser-485, thus inhibiting AMPK activation via phosphorylation at Thr-172. It is possible that this contri- butes to the elevated risk of hepatocellular carcinoma observed in humans with chronic HCV infection. Finally, we have found that AMPK is directly activated by salicylate, and have evidence that at least some of the metabolic changes induced by the drug in vivo are mediated by AMPK. Salicylate is a natural product of plants whose medicinal use was described in ancient manuscripts. Its use has largely been replaced by deriva- tives such as salsalate and aspirin, but both are rapidly broken down to salicylate in vivo. It is possible that some of the beneficial effects of salicylate derivatives, including amelioration of insulin resistance and protection against colon cancer, might be mediated by AMPK. Published: 1 June 2012 doi:10.1186/1753-6561-6-S3-O10 Cite this article as: Hardie: AMPK - a nutrient and energy sensor with roles in diabetes, cancer and viral infection. BMC Proceedings 2012 6 (Suppl 3):O10. College of Life Sciences, University of Dundee, Dundee, Scotland, UK Hardie BMC Proceedings 2012, 6(Suppl 3):O10 http://www.biomedcentral.com/1753-6561/6/S3/O10 © 2012 Hardie; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

AMPK - a nutrient and energy sensor with roles in diabetes, cancer and viral infection

  • Upload
    grahame

  • View
    214

  • Download
    0

Embed Size (px)

Citation preview

Page 1: AMPK - a nutrient and energy sensor with roles in diabetes, cancer and viral infection

ORAL PRESENTATION Open Access

AMPK - a nutrient and energy sensor with rolesin diabetes, cancer and viral infectionGrahame Hardie

From Metabolism, diet and diseaseWashington, DC, USA. 29-31 May 2012

The AMP-activated protein kinase (AMPK) is a cellularenergy sensor that is conserved throughout the eukaryoticdomain. AMPK exists as complexes comprising catalytic asubunits and regulatory b and g subunits, which are acti-vated >100-fold by phosphorylation of the a subunit atThr-172 by upstream kinases. Binding of AMP to one siteon the Y subunit causes 10-fold allosteric activation byAMP, while binding of either AMP or ADP to a secondsite promotes phosphorylation and inhibits dephosphory-lation of Thr-172. Since both effects are antagonized byATP, the kinase is activated by falling cellular energy sta-tus, when it phosphorylates downstream targets thatswitch on catabolic pathways generating ATP, whileswitching off processes consuming ATP. Catabolic pro-cesses switched on including uptake and metabolism ofglucose and fatty acids, and mitochondrial biogenesis.ATP-consuming processes switched off include biosyn-thetic pathways for lipids (fatty acids, phospholipids, cho-lesterol), carbohydrates (gluconeogenesis, glycogensynthesis), proteins and ribosomal RNA, and progressthrough the cell cycle.By switching on glucose and fatty acid uptake and meta-

bolism and switching off gluconeogenesis, AMPK shouldreverse the key metabolic defects in insulin resistance andtype 2 diabetes. Consistent with this, AMPK is a target,although probably not the only target, for the anti-diabeticdrug metformin. Because AMPK activation inhibits mostbiosynthetic pathways and causes cell cycle arrest, itshould also have a cytostatic, tumor suppressor effect. Thediscovery in 2003 that the major upstream kinase thatphosphorylates Thr-172 is the tumor suppressor kinase,LKB1, strengthened this view. The finding also led to ret-rospective analyses suggesting that metformin protectsagainst the development of cancer.

If AMPK is a tumor suppressor, one would expect that itwould be down-regulated in many tumors. This indeedoccurs through loss-of-function mutations in the upstreamkinase LKB1, particularly in non-small cell lung cancerand cervical cancer. The majority of cases of breast canceralso appear to have defects in AMPK activation, althoughthe mechanism is not known. We have found that AMPKis down-regulated in cells infected with hepatitis C virus(HCV). HCV may switch off AMPK to prevent its inhibi-tory effects on lipid and protein synthesis, required forviral replication. HCV infection activates the PKB/Aktpathway, leading to phosphorylation of the a1 subunit ofAMPK on Ser-485, thus inhibiting AMPK activation viaphosphorylation at Thr-172. It is possible that this contri-butes to the elevated risk of hepatocellular carcinomaobserved in humans with chronic HCV infection.Finally, we have found that AMPK is directly activated

by salicylate, and have evidence that at least some of themetabolic changes induced by the drug in vivo aremediated by AMPK. Salicylate is a natural product ofplants whose medicinal use was described in ancientmanuscripts. Its use has largely been replaced by deriva-tives such as salsalate and aspirin, but both are rapidlybroken down to salicylate in vivo. It is possible that someof the beneficial effects of salicylate derivatives, includingamelioration of insulin resistance and protection againstcolon cancer, might be mediated by AMPK.

Published: 1 June 2012

doi:10.1186/1753-6561-6-S3-O10Cite this article as: Hardie: AMPK - a nutrient and energy sensor withroles in diabetes, cancer and viral infection. BMC Proceedings 2012 6(Suppl 3):O10.

College of Life Sciences, University of Dundee, Dundee, Scotland, UK

Hardie BMC Proceedings 2012, 6(Suppl 3):O10http://www.biomedcentral.com/1753-6561/6/S3/O10

© 2012 Hardie; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative CommonsAttribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction inany medium, provided the original work is properly cited.